Mechanistic Studies of Chronic COPD Using Single-Cell Sequencing and Single-Cell Spatial Transcriptomics
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: COPD. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Bidirectional Cohort Study of Single-Cell Sequencing and Single-Cell Spatial Transcriptomics in Chronic COPD
Overview
This study is an ambispective cohort study, the sample from patients were from both previously stored and freshly collected . The objective of this study is to investigate the molecular pathological changes underlying the development of chronic obstructive pulmonary disease (COPD). We will use single cell sequencing technology to analyze lung tissue samples from patients who underwent lung resection, with lung tissue from patients without COPD serving as controls. This research aims to provide insights into the pathogenesis of COPD.
Primary outcome measures
- Transcriptomic profile analysis of lung tissues [Time frame: until end of surgery]
Eligibility criteria
Inclusion criteria
- Receiving lung resection surgery at the hospital for any reason；
- Diagnosed with COPD according to the 2024 GOLD guidelines；
- Tissue samples that meet collection requirements and are either agreed to be collected or already preserved；
Exclusion criteria
- Improper preservation of pathological specimens, refusal to consent to sample collection, or incomplete clinical information；
- Combined with other factors causing obstructive airflow limitation;
- Diagnosed with asthma according to the GINA 2023 guidelines and with a history of asthma exacerbations within the past year;
- Combined with Advanced lung cancer;
- Receiving systemic immunosuppressive medications such as anti-rejection drugs;
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Other
Study locations
China · 1 center
- Renji Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai
Identifiers
NCT: NCT07208123 · HSCRNACOPD-001